Increased aortic stiffness and blood pressure in non-classic Pompe disease by Stephan C. A. Wens et al.
ORIGINAL ARTICLE
Increased aortic stiffness and blood pressure in non-classic
Pompe disease
Stephan C. A. Wens & Esther Kuperus & Francesco U. S. Mattace-Raso &
Michelle E. Kruijshaar & Esther Brusse & Kees C. A. G. M. van Montfort &
Marjan Scheltens- de Boer & Eric J. G. Sijbrands & Ans T. van der Ploeg &
Pieter A. van Doorn
Received: 10 September 2013 /Revised: 19 November 2013 /Accepted: 22 November 2013 /Published online: 10 January 2014
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Vascular abnormalities and glycogen accumulation
in vascular smooth muscle fibres have been described in
Pompe disease. Using carotid-femoral pulse wave velocity
(cfPWV), the gold standard methodology for determining
aortic stiffness, we studied whether aortic stiffness is increased
in patients with Pompe disease. Eighty-four adult Pompe
patients and 179 age- and gender-matched volunteers partic-
ipated in this cross-sectional case-controlled study. Intima
media thickness and the distensibility of the right common
carotid artery were measured using a Duplex scanner. Aortic
augmentation index, central pulse pressure, aortic reflexion
time and cfPWV were assessed using the SphygmoCor®
system. CfPWV was higher in patients than in volunteers
(8.8 versus 7.4 m/s, p <0.001). This difference was still pres-
ent after adjustment for age, gender, mean arterial blood
pressure (MAP), heart rate and diabetes mellitus (p =0.001),
and was shown by subgroup analysis to apply to the 40-
59 years age group (p =0.004) and 60+ years age group (p =
0.01), but not to younger age groups (p =0.99). Except for a
shorter aortic reflexion time (p =0.02), indirect indicators of
arterial stiffness did not differ between patients and volun-
teers. Relative to volunteers (20 %), more Pompe pa-
tients had a history of hypertension (36 %, p =0.005),
and the MAP was higher than in volunteers (100 versus
92 mmHg, p <0.001). This study shows that patients
with non-classic Pompe disease have increased aortic
stiffness and blood pressure. Whether this is due to
glycogen accumulation requires further investigation.
To reduce the potential risk of cardiovascular diseases,
we recommend that blood pressure and other common
cardiovascular risk factors are monitored regularly.
Abbreviations
AIx augmentation index
ATr aortic reflexion time
CfPWV carotid-femoral pulse wave velocity
DBP diastolic blood pressure
ERT enzyme replacement therapy
IMT intima media thickness
MAP mean arterial blood pressure
PAS periodic acid-Schiff
PPc central pulse pressure
PWA pulse wave analysis
SBP systolic blood pressure
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Introduction
Pompe disease (OMIM 232300: acid maltase deficiency or
glycogen storage disease type II) is an inheritable lysosomal
storage disorder caused by a deficiency of acid α-glucosidase
that leads to glycogen accumulation in various body tissues,
predominantly skeletal, cardiac and smooth muscle
(Hirschhorn 2001; van der Ploeg and Reuser 2008). Patients
with the classic-infantile form of the disease develop general-
ized hypotonia and a hypertrophic cardiomyopathy. Without
treatment, these patients die in the first year of life due to
cardiorespiratory failure (van den Hout et al 2003). In the non-
classic form of the disease, which can present at any age,
progressive muscle weakness is the predominant symptom.
In general, there is no significant cardiac involvement
(Soliman et al 2008; van der Beek et al 2012).
Over the last two decades, several reports have hypothe-
sized that glycogen accumulation in the smooth muscle tissue
of arteries leads to vascular abnormalities in non-classic
Pompe disease, such as cerebral aneurysms, basilar artery
dolichoectasia, carotid dissection and dilated arteriopathy of
the thoracic aorta (Braunsdorf 1987; Winkel et al 2003, 2005;
Laforet et al 2008; Sacconi et al 2010; El-Gharbawy et al
2011). The first indication of increased aortic stiffness in non-
classic Pompe disease was reported in a study on 17 Pompe
patients that used transthoracic Doppler echocardiography, a
non-invasive tool that measures aortic stiffness indirectly
(Nemes et al 2007). The presence of increased aortic stiffness
may be relevant, since it is considered to be an independent
risk factor for cardiovascular disease and mortality (Mattace-
Raso et al 2006; Verbeke et al 2011). The emerging gold
standard for measuring it directly and non-invasively is to-
nometry of the carotid-femoral pulse wave velocity (cfPWV)
(Van Bortel et al 2012).
To determine whether increased arterial stiffness is a fea-
ture of non-classic Pompe disease, we used various techniques
including tonometry of the cfPWV to investigate the structural
and functional vascular properties of different vascular terri-
tories in a large group of patients with non-classic Pompe




Between March 2012 and June 2013 we performed a cross-
sectional single-centre case-controlled study in 84 patients
with non-classic Pompe disease and 179 volunteers. All pa-
tients were 18 years or older. As the volunteers were matched
for gender and age category, there were, per patient, at least
two volunteers of the same gender and the same age category.
The volunteers were either the patients’ partners, or were
employees or students of Erasmus University Medical Center,
or otherwise visitors to it. Informed consent was obtained
from all participants. The study protocol was approved by
the Medical Ethical Committee at Erasmus University Medi-
cal Center
Cardiovascular risk factors
All participants filled out a questionnaire to assess cardiovas-
cular risk factors, which included gender, date of birth, length,
weight, medication use, and comorbidities such as hyperten-
sion, diabetes mellitus, hypercholesterolemia and cardiovas-
cular disease (i.e. transient ischemic attack, stroke, myocardial
infarction or rhythm disturbances). Body mass index (BMI),
which was calculated as body weight divided by height
squared, was expressed as kg/m2. An automatic mercury cuff
sphygmomanometer on the right arm was used to measure
heart rate and blood pressure, including the mean arterial
blood pressure (MAP), when the patient was in supine posi-
tion after 5 min of rest in a quiet and heat-controlled room.
Hypertensionwas defined as a systolic blood pressure (SBP)>
140 mmHg and/or diastolic blood pressure (DBP)>90 mmHg
(Mancia et al 2013).
Vascular measurements
Aortic stiffness was measured using arterial tonometry from
the right radial, right carotid and right femoral arteries using
the SphygmoCor® device (Sphygmocor version 7.1, AtCor
Medical, Sydney, Australia) according to previously described
procedures (van Dijk et al 2013). Transit distance was
assessed on the basis of body surface measurement from the
carotid artery to the femoral artery: 80 % of this distance was
used as pulse-wave-travelled distance (Van Bortel et al 2012).
The primary outcome measure, cfPWV, was expressed in
meters per second (m/s). The secondary and indirect outcome
parameters for arterial stiffness measured with pulse wave
analysis (PWA) of the right radial artery were central pulse
pressure (PPc), augmentation index (AIx) and aortic reflexion
time (ATr). PPc was calculated as the difference between
aortic systolic and diastolic pressure; AIx was calculated from
the aortic pressure waveform obtained by applying a general
transfer function to the radial pressure waveform. For the
comparison between two groups, AIx was normalized to a
heart rate of 75 beats per minute. ATr was calculated as the
time interval between the foot of the pressure wave and the
shoulder of the reflected wave (Laurent et al 2006; DeLoach
and Townsend 2008; Huijben et al 2012).
The distensibility and IMT of the right common carotid
artery were measured two centimetres below the carotid bi-
furcation using a vessel-wall movement-detector system
(Art.Lab, Esaote Europe, Maastricht, the Netherlands)
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according to previously described procedures (van Dijk et al
2013). The distensibility coefficient, a local measurement of
carotid stiffness, was calculated as (2ΔD/D)/PP(10−3/kPa)
(Hoeks et al 1992), in which D is the diameter during diastole,
ΔD is the measured distensibility (systolic diameter – diastol-
ic diameter), and PP is the aortic pulse pressure derived from
radial applanation. Tonometry and ultrasonography were per-
formed by two trained physicians (SW or EK).
Statistical analyses
Unless otherwise specified, data are presented asmedians with
interquartile ranges (IQR). Because cfPWV, PPc, AIx, ATr,
distensibility and IMT were not normally distributed, the
Mann–Whitney test was used to compare these outcomes
between the total groups of patients and volunteers.
Linear regression analyses were used to study cfPWV
separately. First, univariate regression analyses were per-
formed. Next, the regression coefficients with a p-value less
than 0.05 or variables that were considered clinically relevant
were analysed in a multivariate regression model using boot-
strap estimation. The final multivariate model contained age,
gender, MAP, heart rate and diabetes mellitus.
We also performed a stratified analysis between patients
and volunteers in three age groups: 20-39, 40-59 and 60+. To
determine whether cfPWV was influenced by disease dura-
tion, treatment with ERT, and wheelchair or ventilator depen-
dency, we also analysed cfPWV in separate multivariate re-
gression models using bootstrap estimation. The final model
for these analyses included four variables: age, gender, MAP
and heart rate. The data were analysed using SPSS 20. A p-
value of less than 0.05 was considered statistically significant.
Results
Study population
Table 1 shows the characteristics of the two groups. In total,
84 patients with non-classic Pompe disease and 179 volun-
teers were included in the study. Twenty-six percent of the
patients were wheelchair dependent, and 31 % needed artifi-
cial ventilation. Eighty-two percent of the patients were treat-
ed with ERTand the median duration of treatment was 5 years
(IQR 4-5). CfPWV could not be measured in nine patients,
either because they could not lie in supine position due to
respiratory failure, or because their use of accessory muscles
made it difficult to visualize the carotid artery. Neither could
cfPWV be measured in the other eight volunteers due to
temporary technical problems with the SphygmoCor®
system.
Cardiovascular risk factors
In the past, more patients with Pompe disease than volunteers
had been diagnosed with hypertension (p =0.005, Table 1).
Seventy-seven per cent of the Pompe patients with an earlier
diagnosis of hypertension used antihypertensive medication at
the time of evaluation, and 89 % in the group of volunteers.
Despite treatment with antihypertensive medication, blood
pressure continued to be high in 52 % of the Pompe patients
who were treated for hypertension and in 65 % of the volun-
teers. As Table 2 shows, MAP was higher in patients than in
volunteers (100 mmHg (IQR 90-111) versus 92 mmHg (IQR
84-103), p <0.001). Thirty-nine per cent of the patients met
the criteria for hypertension (SBP>140 mmHg and/or DBP>
90 mmHg), versus 20 % of the volunteers (p =0.001). At
group level, patients with Pompe disease had a higher heart
rate (75 beats per minute (bpm) (IQR 68-83)) than the volun-
teers (65 bpm (IQR 59-71), p <0.001).
There were no differences in the occurrence of comorbid-
ities such as diabetes mellitus or hypercholesterolemia. Seven
patients with Pompe disease had a medical history of cardio-
vascular disease: four of them (three female) had had a tran-
sient ischemic attack between the ages of 48 and 62 years);
two male patients had developed atrial fibrillation at the ages
of 37 and 64 years; and one female patient had had a
Table 1 Demographic and clinical characteristics
Pompe patients Volunteers
Number of individuals 84 179
Age in years 54 (42-63) 54 (41-61)
Gender – male (%) 41 (49) 85 (48)
Body mass index in kg/m2 24.7 (22.0-27.3) 24.0 (22.2-26.0)
Smoking status (%)
▪ Never 36 (43) 107 (60)
▪ Past 41 (49) 53 (29)
▪ Current 7 (8) 19 (11)
Medical history
▪ Hypertension (%) 30 (36)a 35 (20)
▪ Diabetes mellitus (%) 5 (6) 6 (3)
▪ Hypercholesterolemia (%) 8 (10) 18 (10)
▪ Cardiovascular disease (%) 7 (8) 9 (5)
Antihypertensive medication (%) 23 (77) 31 (89)
Disease duration in years 16 (12-23) -
Patients receiving ERT (%) 69 (82) -
Duration of ERT in years 5 (4-5) -
Wheelchair use (%) 22 (26) 0 (0)
Ventilator use (%) 26 (31) 0 (0)
Continuous variables are given as medians with interquartile ranges
(IQR), and categorical variables as numbers and percentages
a In the past, more patients with Pompe disease than volunteers were
diagnosed with hypertension (p-0.005)
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myocardial infarction at the age of 74 years. Nine volunteers
had a medical history of cardiovascular disease. This was not
statistically different from the seven Pompe patients (p =0.30).
Aortic stiffness
As shown in Table 2, median cfPWV was 8.8 m/s in patients
with Pompe disease (IQR 7.1-10.7) and 7.4 m/s in volunteers
(IQR 6.6-8.6) (p <0.001). This difference was still present
after adjustment for age, gender, MAP, heart rate and diabetes
mellitus (p =0.001). Subgroup analysis showed that while it
occurred in the 40-59 years age group (8.6 m/s in patients
versus 7.6 m/s in volunteers, p =0.004) and the 60+ years
(11.5 versus 9.3 m/s, p =0.01), it did not occur in the 20-
39 years age group (Fig. 1). PPc and AIx did not differ
significantly between patients and volunteers, while ATr was
shorter in patients than in volunteers (p =0.02).
CfPWV did not differ between Pompe patients whose
disease duration was shorter than 15 years (n =35) and those
whose disease duration was longer than 15 years (n =44) (9.1
versus 9.4 m/s, p =0.51). Neither did it differ between patients
treated with ERT (n =64) and treatment-naïve patients (n =15)
(9.4 versus 8.6 m/s, p =0.17). Similarly, cfPWV did not differ
between wheelchair-dependent patients (n =12) and ambulant
patients (n =62) (9.4 versus 9.2 m/s, p =0.75), or between
ventilator-dependent patients (n =18) and non-ventilated pa-
tients (n =56) (9.6 versus 9.1 m/s, p =0.42).
Carotid stiffness and IMT
Table 2 shows that there were no significant differences in
distensibility or IMT between patients and volunteers. The
diameter of the carotid artery was smaller in patients than in
volunteers (6.6 mm (IQR 6.1-7.3) versus 7.1 mm (IQR 6.5-
7.8), p <0.001). Subgroup analysis showed that the distensi-
bility was lower in patients with Pompe disease aged between
20 and 39 years than in volunteers (p =0.03), but not in the
other age-related subgroups.
Glycogen accumulation in vascular smooth muscle
Figure 2 shows the muscle biopsy of a 50-year-old male
patient with Pompe disease who participated in this study
and had no medical history of cardiovascular diseases. He
developed the first symptoms at age 44, and now has severe
limb-girdle weakness and decreased pulmonary function in
sitting and supine positions. The biopsy was stained with
periodic acid-Schiff (PAS) and shows glycogen storage in
skeletal muscle fibres and in vascular smooth muscle fibres.
Discussion
We found that patients with the non-classic form of Pompe
disease have increased aortic stiffness and blood pressure.
These findings indicate clinical relevant involvement of the
cardiovascular musculature in this group of Pompe patients.
Glycogen accumulation in smooth muscle fibres and in the
endothelial layer of arteries has been shown in morphological
studies and autopsy reports of patients with Pompe disease
(Winkel et al 2003; Thurberg et al 2006; Kobayashi et al
2010). Figure 2 shows glycogen storage in vascular smooth
muscle fibres in one of our adult patients with Pompe disease
before the start of ERT. While it is likely that the increased
glycogen storage in smooth muscle fibres results in an in-
creased arterial stiffness, it is also possible that glycogen
accumulation in the endothelium damages the vascular wall,
making it more vulnerable to atherosclerosis; in the presence
of other cardiovascular risk factors, this process might in-
crease arterial stiffness. As vascular stiffness has also been
described as depending on the distribution of collagen and
elastin, an increase in abnormal collagen and a decrease in
Table 2 Functional and structural hemodynamic parameters in patients and volunteers
Pompe patients (n =84) Volunteers (n =179) P-value
Mean arterial pressure (mmHg) 100 (90-111) 92 (84-103) <0.001
Heart rate (beats per minute) 75 (68-83) 65 (59-71) <0.001
Diameter carotid artery (mm) 6.6 (6.1-7.3) 7.1 (6.5-7.8) <0.001
Intima media thickness (μm) 582 (514-683) 592 (506-695) 0.68
Distensibility coefficient (10−3/kPa) 2.9 (1.9-4.1) 2.7 (2.2-4.1) 0.72
Carotid-femoral pulse wave velocity (m/s) 8.8 (7.1-10.7) 7.4 (6.6-8.6) <0.001
Central pulse pressure (mmHg) 38 (31-47) 36 (31-43) 0.30
Augmentation index (%) 21.7 (13.2-30.3) 19.4 (8.5-29.4) 0.23
Aortic reflexion time (ms) 140 (132-149) 144 (135-159) 0.02
Continuous variables are given as medians with interquartile ranges (IQR). The diameter of the carotid artery was measured in 179 volunteers and 84
patients; IMTwas measured in 179 volunteers and 83 patients; the distensibility coefficient was measured in 176 volunteers and 80 patients; cfPWVwas
measured in 171 volunteers and 79 patients; and PPc, Aix and ATr were measured in 178 volunteers and 83 patients
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normal elastin contributes to greater arterial stiffness (Laurent
et al 2006). During the course of the disease, patients with
Pompe disease may develop striated muscle atrophy with
some increase in connective tissue. If this process also oc-
curred in the vascular smoothmuscle fibres of Pompe patients,
it would help to explain increased aortic stiffness.
Increased aortic stiffness has also been described in other
lysosomal storage disorders such as Fabry disease and
mucopolysaccharidosis type I (MPS I or Scheie syndrome).
In Fabry disease, storage of glycosphingolipids takes place in
vascular endothelial and smooth muscle cells, and in MPS I,
accumulation of glycosaminoglycans in the connective tissue
of the aortic wall impairs the formation of elastin and leads to
changes in collagen formation (Nemes et al 2008; Collin et al
2012). It has been shown in Fabry disease that ERT can
normalize aortic stiffness (Collin et al 2012). As most of the
patients with Pompe disease enrolled in our cross-sectional
study were treated with ERT, the difference in cfPWV be-
tween patients and volunteers might have been even more
pronounced if it had been measured before the start of ERT. It
would thus be interesting to establish whether aortic stiffness
in Pompe patients decreases during ERT, and whether cfPWV
can be used as a non-invasive tissue biomarker for disease
progression and therapy response.
To the best of our knowledge, this is the first study to show
that arterial blood pressure is increased in patients with Pompe
disease. It is reasonable to assume that any structural changes
in the blood vessels caused by the increased aortic stiffness
would lead to higher blood pressure. Increased aortic stiffness
and hypertension are both independent risk factors for cardio-
vascular disease and mortality (Mattace-Raso et al 2006;
Verbeke et al 2011). It has been shown that patients with
non-classic Pompe disease have improved survival when
treated with ERT (Güngör et al 2013). Since cardiovascular
diseases are more common at a higher age, Pompe patients
will be more likely to develop cardiovascular diseases, as they
owe their higher age to ERT. In these patients it is therefore
important to closely monitor risk factors for cardiovascular
diseases such as hypertension, hypercholesterolemia, diabetes
mellitus and smoking, and to treat them when indicated.
Although exercise and training, dietary changes and pharma-
cological treatments have sometimes been shown to reduce
arterial stiffness in healthy individuals and other patient
groups (Kingwell et al 1997; Girerd et al 1998; Balkestein
et al 1999), it has not yet been investigated whether they are
also beneficial in Pompe patients.
Although we expected Pompe disease to have a similar
effect on the vascular structure of all arteries, and thereby to
increase cfPWV and reduce distensibility, we found changes
in carotid distensibility only in patients aged between 20 and
39 years. In those with high blood pressure and diabetes it has
been reported that the aorta stiffened more than the carotid
Fig. 1 Mean values of cfPWV in
patients and volunteers per age
category. The boxplots represent
the mean values and 95 % CI of
cfPWV per age category after
adjustment for age, gender, mean
arterial blood pressure, heart rate
and diabetes mellitus. The
number of patients and volunteers
per age group are given in the
bars
Fig. 2 Glycogen accumulation in
vascular smooth muscle fibres.
Muscle biopsies of adult patients
with non-classic Pompe disease
stained with periodic acid-Schiff
(PAS) to demonstrate glycogen
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artery with age and with other cardiovascular risk factors such
as increased body mass index and heart rate (Paini et al 2006).
These findings may have been paralleled by our own finding
in most of the Pompe patients whose blood pressure and heart
rate were increased, who also had greater aortic stiffness
without decreased distensibility.
A strength of our study is that we used cfPWV, which is
currently the gold standard for measuring aortic stiffness
directly and non-invasively in a relatively large group of
Pompe patients. A previous study that found increased aortic
stiffness in a small group of patients with Pompe disease used
transthoracic echocardiography, an indirect way of measuring
aortic stiffness (Nemes et al 2007).
Our study has some limitations. First, due to physical or
temporary technical problems, measurements of aortic stiff-
ness were not available for all subjects. However, as most of
the patient data that were missing in the group of Pompe
patients were those for the elderly and more severely affected
patients, this would probably have led to an underestimation
of the real difference in aortic stiffness between Pompe pa-
tients and healthy volunteers. Second, as this was a cross-
sectional study, we do not know about the progression of
aortic stiffness over time, or about the effects of ERTon aortic
stiffness. Additionally, rather than measuring glucose or cho-
lesterol in blood samples, we used a questionnaire to establish
whether patients had a history of hypercholesterolemia or
diabetes mellitus.
In conclusion, patients with non-classic Pompe disease
have increased aortic stiffness and blood pressure. To reduce
the potential risk of cardiovascular diseases, we recommend
that blood pressure and other common cardiovascular risk
factors are monitored closely. Prospective studies should in-
vestigate whether ERT reduces aortic stiffness, or whether
early treatment even prevents it.
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